Baird Medical's AI Tumor Ablation Surgical Robot Wins "Most Valuable Investment Award," Pioneering AI and Robotics Integration in Healthcare
Baird Medical (NASDAQ: BDMD) has received the 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition for its innovative AI Tumor Ablation Surgical Robot. The system integrates multimodal AI algorithms with high-precision robotic arm control, featuring autonomous decision-making and dynamic optimization capabilities.
Key technological advantages include:
- Integration of over 100,000 tumor ablation image cases and 50,000 pathology reports
- Federated learning technology enabling secure global data sharing
- Future quantum-optimized pretraining capabilities
The project combines expertise from Nanyang Technological University, oncologic surgeons, and AI engineers from the Chinese Academy of Sciences, with over 90 filed patents. The system will undergo clinical simulations across 20 top-tier hospitals globally and includes an AI-powered surgical ethics decision module targeting surgical complications below 1%. Applications extend beyond tumor ablation to neurosurgery and urology, with planned regulatory approvals in 30+ countries.
Baird Medical (NASDAQ: BDMD) ha ricevuto il 'Premio Investimento Più Prezioso' alla 10ª Competizione per l'Innovazione nell'Industria Medica in Cina per il suo innovativo Robot Chirurgico per Ablazione Tumorale con IA. Il sistema integra algoritmi di intelligenza artificiale multimodali con un controllo di braccio robotico ad alta precisione, dotato di capacità di decisione autonoma e ottimizzazione dinamica.
I principali vantaggi tecnologici includono:
- Integrazione di oltre 100.000 casi di immagini di ablazione tumorale e 50.000 rapporti patologici
- Tecnologia di apprendimento federato che consente la condivisione sicura dei dati a livello globale
- Futuri capacità di pre-addestramento ottimizzate per il quantum
Il progetto combina competenze della Nanyang Technological University, chirurghi oncologici e ingegneri di IA dell'Accademia Cinese delle Scienze, con oltre 90 brevetti depositati. Il sistema sarà sottoposto a simulazioni cliniche in oltre 20 ospedali di alto livello a livello globale e include un modulo decisionale etico chirurgico potenziato dall'IA mirato a ridurre le complicazioni chirurgiche sotto l'1%. Le applicazioni si estendono oltre l'ablazione tumorale alla neurochirurgia e all'urologia, con approvazioni normative pianificate in oltre 30 paesi.
Baird Medical (NASDAQ: BDMD) ha recibido el 'Premio a la Inversión Más Valiosa' en la 10ª Competencia de Innovación de la Industria Médica de China por su innovador Robot Quirúrgico de Ablación Tumoral con IA. El sistema integra algoritmos de IA multimodal con control de brazo robótico de alta precisión, presentando capacidades de toma de decisiones autónomas y optimización dinámica.
Las principales ventajas tecnológicas incluyen:
- Integración de más de 100,000 casos de imágenes de ablación tumoral y 50,000 informes patológicos
- Tecnología de aprendizaje federado que permite el intercambio seguro de datos a nivel global
- Futuras capacidades de preentrenamiento optimizadas para quantum
El proyecto combina la experiencia de la Universidad Tecnológica de Nanyang, cirujanos oncológicos e ingenieros de IA de la Academia China de Ciencias, con más de 90 patentes presentadas. El sistema se someterá a simulaciones clínicas en más de 20 hospitales de primer nivel a nivel mundial e incluye un módulo de decisión ética quirúrgica potenciado por IA que tiene como objetivo reducir las complicaciones quirúrgicas por debajo del 1%. Las aplicaciones se extienden más allá de la ablación tumoral a la neurocirugía y la urología, con aprobaciones regulatorias planificadas en más de 30 países.
베어드 메디컬 (NASDAQ: BDMD)는 혁신적인 AI 종양 절제 수술 로봇
주요 기술적 이점은 다음과 같습니다:
- 10만 건 이상의 종양 절제 이미지 사례와 5만 건의 병리 보고서 통합
- 안전한 글로벌 데이터 공유를 가능하게 하는 연합 학습 기술
- 미래의 양자 최적화 사전 훈련 기능
이 프로젝트는 난양기술대학교, 종양외과 의사 및 중국과학원 AI 엔지니어의 전문 지식을 결합하며, 90건 이상의 특허가 출원되었습니다. 이 시스템은 전 세계 20개 이상의 최고 병원에서 임상 시뮬레이션을 진행할 예정이며, 1% 이하의 수술 합병증을 목표로 하는 AI 기반 수술 윤리 결정 모듈을 포함하고 있습니다. 응용 분야는 종양 절제 외에도 신경외과 및 비뇨기과로 확장되며, 30개 이상의 국가에서 규제 승인이 계획되고 있습니다.
Baird Medical (NASDAQ: BDMD) a reçu le 'Prix de l'Investissement le Plus Précieux' lors de la 10ème Compétition d'Innovation de l'Industrie Médicale en Chine pour son innovant Robot Chirurgical d'Ablation Tumorale avec IA. Le système intègre des algorithmes d'IA multimodaux avec un contrôle de bras robotique haute précision, offrant des capacités de prise de décision autonome et d'optimisation dynamique.
Les principaux avantages technologiques incluent:
- Intégration de plus de 100 000 cas d'images d'ablation tumorale et 50 000 rapports pathologiques
- Technologie d'apprentissage fédéré permettant un partage sécurisé des données à l'échelle mondiale
- Futures capacités de pré-entraînement optimisées pour le quantique
Le projet combine l'expertise de l'Université Technologique de Nanyang, de chirurgiens oncologiques et d'ingénieurs en IA de l'Académie Chinoise des Sciences, avec plus de 90 brevets déposés. Le système sera soumis à des simulations cliniques dans plus de 20 hôpitaux de premier plan à l'échelle mondiale et comprend un module de décision éthique chirurgicale alimenté par l'IA visant à réduire les complications chirurgicales à moins de 1%. Les applications s'étendent au-delà de l'ablation tumorale à la neurochirurgie et à l'urologie, avec des approbations réglementaires prévues dans plus de 30 pays.
Baird Medical (NASDAQ: BDMD) hat den 'Most Valuable Investment Award' beim 10. China Medical Industry Innovation Competition für seinen innovativen AI-Tumor-Ablationschirurgieroboter erhalten. Das System integriert multimodale KI-Algorithmen mit hochpräziser Roboterarmsteuerung und verfügt über autonome Entscheidungsfindung sowie dynamische Optimierungsfähigkeiten.
Die wichtigsten technologischen Vorteile sind:
- Integration von über 100.000 Tumorablationsbildfällen und 50.000 Pathologieberichten
- Föderierte Lerntechnologie, die sichere globale Datenfreigabe ermöglicht
- Zukünftige quantenoptimierte Vortrainingsfähigkeiten
Das Projekt kombiniert Fachwissen der Nanyang Technological University, Onkologen und KI-Ingenieuren der Chinesischen Akademie der Wissenschaften, mit über 90 eingereichten Patenten. Das System wird klinischen Simulationen in über 20 erstklassigen Krankenhäusern weltweit unterzogen und umfasst ein KI-gestütztes ethisches Entscheidungsmodul für chirurgische Eingriffe, das darauf abzielt, chirurgische Komplikationen unter 1% zu halten. Die Anwendungen reichen über die Tumorablation hinaus bis zur Neurochirurgie und Urologie, mit geplanten behördlichen Genehmigungen in über 30 Ländern.
- None.
- None.
AI & Robotics: Redefining the Paradigm of Precision Medicine
Baird Medical's AI Tumor Ablation Surgical Robot will be an intelligent surgical system that seamlessly integrates multimodal AI algorithms with high-precision robotic arm control. Its key innovations will include:
- Autonomous Decision-Making & Dynamic Optimization – Using an AI-powered real-time learning framework, the system simultaneously analyzes intraoperative imaging, physiological data, and thermal field simulations to dynamically adjust ablation parameters with millimeter-level precision.
- Multi-Technology Synergy Platform – Integrating microwave, radiofrequency, laser, and nano-knife ablation technologies, the AI algorithm optimizes surgical site selection, nodule characteristics, energy output, and ablation method, overcoming the limitations of traditional single-technique approaches.
- End-to-End Intelligent Automation: Leveraging AI-driven precision, the system seamlessly integrates preoperative 3D lesion segmentation, millimeter-level path planning, and intraoperative micron-level fully automated surgery, followed by predictive postoperative outcome analysis. Surgeons serve as overseers, intervening only at critical junctures in a passive mode as needed. This transformative approach will effectively enhance surgical efficiency.
As the "brain" of the system, Baird Medical's proprietary AI-driven platform will offer three key technological advantages:
- Establishing an Extensive Medical Knowledge Base – Integrates over 100,000 tumor ablation image cases and 50,000 pathology reports, enabling cross-modal data correlation and in-depth analysis.
- Building a Self-Evolving Learning Architecture – Utilizes federated learning technology to enable secure data sharing across global partner hospitals, reducing model iteration cycles to just a few weeks.
- Implementing Quantum-Optimized Pretraining – In future collaboration with quantum computing centers, leverages quantum optimization algorithms to overcome the computational bottlenecks of traditional deep learning, significantly accelerating inference speed.
World-Class R&D Team & Cutting-Edge Development: A Milestone in Medical Technology
This project will actively implement Baird Medical's R&D strategy of "Global Expertise + Local Innovation," built on three core pillars.
- Building an Elite Interdisciplinary Team – Bringing together top-tier medical robotics experts from Nanyang Technological University, globally renowned oncologic surgeons, and former AI algorithm engineers from the Chinese Academy of Sciences. This core team has deep expertise in AI-driven medical applications and has collectively filed over 90 patents.
- Establishing a Comprehensive Validation Framework – Implementing rigorous multi-center clinical simulations across 20 top-tier hospitals in the
U.S. ,Europe , andChina to ensure the system's safety, reliability, and efficacy in complex surgical environments. - Advancing an Ethics-Driven AI Design – Developing the world's first AI-powered surgical ethics decision module, incorporating real-time risk alerts and redundant operation validation to proactively mitigate surgical complications, with a targeted reduction to below
1% .
Expanding Applications: From Tumor Treatment to a Minimally Invasive Revolution
This cutting-edge system extends beyond the precise ablation of solid tumors such as thyroid nodules, breast nodules, liver cancer, and lung cancer—it also marks a breakthrough in chronic pain management. More notably, its modular design is expected to enable rapid adaptation for applications in neurosurgery (e.g., epilepsy lesion localization) and urology (e.g., prostate ablation).
The launch of Baird Medical's AI-powered tumor ablation robotic system represents not only a paradigm shift in the integration of AI and robotics but also a redefinition of excellence in medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system is transforming minimally invasive surgery from an experience-based practice to a data-driven discipline. As commercial deployment expands across 30+ countries, the future of intelligent healthcare is now within reach.
The development of Baird Medical's AI-powered tumor ablation surgical robot will not only set a benchmark for the integration of AI and robotics but also redefine the standards for high-quality medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system aims to transform minimally invasive surgery from an experience-based practice to a data-driven one. If successfully commercialized, the system is expected to initiate regulatory approvals and market expansion across more than 30 countries, bringing the future of intelligent healthcare within reach.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medicals-ai-tumor-ablation-surgical-robot-wins-most-valuable-investment-award-pioneering-ai-and-robotics-integration-in-healthcare-302402336.html
SOURCE BDMD
FAQ
What are the key features of BDMD's AI Tumor Ablation Surgical Robot?
How many clinical cases support BDMD's AI surgical system?
Which medical conditions can BDMD's surgical robot treat?
What is the global expansion plan for BDMD's AI surgical robot?
What is the safety target for BDMD's AI surgical robot?
